A proper diagnosis between bipolar disorder and borderline personality disorder have important implications as treatment decisions differ based on the diagnosis
Unraveling the possible causes and triggers of agitation in people with dementia is worthy of detective work, according to a recent presentation.
The survey results demonstrate an unmet need for new oral antipsychotics with favorable risk-benefit profiles, researchers said.
Clinicians need to keep certain facts about mental illness and unintended pregnancy in mind when treating female patients of reproductive age, said an expert in mental illness, pregnancy, and women's health.
As data continues to show increases in the rates of suicide in the United States, healthcare systems are grappling with addressing the issue in an effective and sustainable way.
Medication adherence is critical not only to clinical outcomes, such as preventing readmissions, but also to containing costs, with adverse outcomes as a result of nonadherence often resulting in higher costs for both the patient and the healthcare system. Ensuring adherence can be especially challenging among people with mood and psychotic disorders.
Jon Grant, MD, JD, MPH, a professor of psychiatry and behavioral neuroscience at the University of Chicago and expert in severe and complex cases of obsessive compulsive disorder, discusses evidence-based approaches to this little-understood disease.
Emerging technologies have the potential to push psychiatry into a new era of evidence-based care, with improved treatment and access.
During the second plenary at the National Association of ACOs fall meeting, Meridith Seife, deputy regional inspector general, Office of Evaluation and Inspections in the HHS Office of the Inspector General, presented results from a government report identifying strategies of high-performing accountable care organizations that had improved care quality while cutting costs.
In the next 5 to 10 years, providers and health systems need to be thinking about how all the pieces of a new system that delivers holistic, value-based care fit together, said Will Shrank, MD, chief medical officer, Humana, during the opening plenary at the National Association of ACOs fall meeting.
To make headroom for expensive, potentially curative therapies in the pipeline, the healthcare needs to remove ineffective care from the system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy.
A joint session of ECTRIMS and the European Academy of Neurology assesses important topics in measuring relapse and progression in multiple sclerosis (MS).
Patients with multiple sclerosis (MS) have a generally increased risk of cardiovascular disease, and some evidence is emerging that disease-modifying treatments may alter this risk. Thomas Frisell, PhD, coordinator of the Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, discusses whether newer treatments for MS, such as ozanimod, may present an improved cardiac safety profile for patients with MS versus older treatments, such as fingolimod.
Multiple sclerosis (MS) can be a challenging disease to diagnose because of its broad range of symptoms and because of the fact that many other syndromes can mimic MS. Additionally, the McDonald Criteria, which are clinical, radiographic, and laboratory criteria used for diagnosing MS, are sometimes misapplied, according to Andrew Solomon, MD, associate professor of neurological sciences and division chief of multiple sclerosis at Larner College of Medicine, The University of Vermont, Burlington, Vermont.
Healthcare does not necessarily need to be disrupted, but it does need to evolve and utilize technology so that cancer care can move beyond the conventional walls of the healthcare delivery system, said Susan Dentzer, visiting fellow at the Duke-Margolis Center for Health Policy, during her keynote speech at the Quality Cancer Care Alliance’s Leadership Summit.
Results for ozanimod, which is under review by FDA and European regulators for treatment of relapsing multiple sclerosis (MS), were presented in poster sessions September 12, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Age is an important factor in the disease burden of multiple sclerosis (MS), as rising age both impacts disease course and brings with it additional risk of comorbidities. However, disease duration may be an even more important factor than age in reaching disability milestones, according to Viktor von Wyl, PhD, project leader, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.
FDA recently accepted the Biologics Licensing Application for inebilizumab to treat a rare autoimmune condition, neuromyelitis optica spectrum disorder. The results for inebilizumab were presented at the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
While current therapies for multiple sclerosis (MS) that treat focal inflammation are beneficial for many patients, there are other crucial aspects of the disease, including brain volume loss, that are not clearly linked to this inflammation and that demand new therapeutic developments, said Jan Hillert, MD, PhD, professor and senior physician in the department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden.
Speakers at a session at ECTRIMS 2019 on long-term outcomes in multiple sclerosis said that better therapies and improved understanding of the effect of comorbidities have improved outcomes. The session was part of the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Maria Trojano, MD, professor of neurology at the University of Bari, Italy, offered the opening lecture at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
A poster featuring a post-hoc exploratory analysis of measures of thalamic volume from RADIANCE was presented September 11, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Addressing comorbidities plays an important role in the management of patients with multiple sclerosis (MS), particularly given their association with hospital admissions. In a study using data from the National Patient Sample, comorbidities were linked with patients’ age, sex, and race and ethnicity, said Deborah Taira, MPA, ScD, professor, Daniel K. Inouye College of Pharmacy, University of Hawai‘i at Hilo.
Some data suggest that pregnancy may be beneficial in the long-term for patients with multiple sclerosis (MS), but there exist periods that may carry an extra risk of relapse, such as before conception and in the postpartum period, according to Marie D’hooghe, MD, PhD, neurologist at the National MS Center, Melsbroek, in Brussels, Belgium, and consultant neurologist at the University Hospital in Brussels, Belgium.
It’s crucial to have support from the numerous community settings that young people interact with so that they can feel understood and better manage their mental illness, according to Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
There are less surprises in the results for performance period 4 of the Oncology Care Model, and practices seem to be mostly happier with how they’ve done, said Mike Fazio, senior vice president of client services, Archway Health.
Early intervention in potential cases of psychosis among young people hinges on multiple settings being aware of the early signs of the illness and able to link people to treatment, said Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.
Jacob Ballon, MD, MPH, clinical associate professor, psychiatry and behavioral sciences, Stanford University, explained how large databases can help researchers understand the variety of psychotic illnesses, potentially leading to more personalized treatments.
Nicholas Robert, MD, medical director of Data, Evidence & Insights, McKesson Life Sciences, discusses how patient-reported outcomes collected through real-world data can provide confirmatory information on newly approved drugs.
When assessing young people for potential early psychosis, psychiatrists should keep in mind that reassurance is particularly important for this patient group, explained Steven Adelsheim, MD, clinical professor of psychiatry and behavioral sciences, Stanford University School of Medicine.